Evogene (NASDAQ:EVGN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Evogene (NASDAQ:EVGN) in a report published on Saturday. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Lake Street Capital cut their target price on shares of Evogene from $30.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, August 23rd.

Evogene Stock Down 6.7 %

Shares of Evogene stock opened at $2.09 on Friday. The business has a fifty day simple moving average of $2.75 and a 200 day simple moving average of $4.90. The stock has a market cap of $8.61 million, a PE ratio of -0.53 and a beta of 1.43. Evogene has a 12 month low of $2.02 and a 12 month high of $10.40.

Evogene (NASDAQ:EVGN) last announced its quarterly earnings results on Thursday, August 22nd. The biotechnology company reported ($1.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.94). Evogene had a negative net margin of 210.26% and a negative return on equity of 72.33%. The company had revenue of $0.91 million during the quarter.

Institutional Investors Weigh In On Evogene

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC acquired a new stake in Evogene Ltd. (NASDAQ:EVGN) in the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors and hedge funds own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.